Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

INTRODUCTION: SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6 mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered with tolerogenic nanoparticles containing sirolimus (rapamycin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivitz, Alan, DeHaan, Wesley, Azeem, Rehan, Park, Justin, Rhodes, Sheri, Inshaw, Jamie, Leung, Sheldon S., Nicolaou, Savvas, Johnston, Lloyd, Kishimoto, Takashi K., Traber, Peter G., Sands, Earl, Choi, Hyon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326180/
https://www.ncbi.nlm.nih.gov/pubmed/37069364
http://dx.doi.org/10.1007/s40744-023-00546-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326180/
https://www.ncbi.nlm.nih.gov/pubmed/37069364
http://dx.doi.org/10.1007/s40744-023-00546-0

Ejemplares similares